SCHEDULE: Carlyle Group Discloses 4.1% Stake in Q32 Bio

The Carlyle Group and its affiliates have reported beneficial ownership of 4.1% of Q32 Bio Inc.'s common stock as of June 18, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Q32 Bio Inc. common stock.
• The Carlyle Group Inc. and several of its affiliated entities (Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L.C., TC Group, L.L.C., Carlyle Investment Management L.L.C., Carlyle Genesis UK LLC) are listed as reporting persons.
• Additionally, Abingworth LLP and Abingworth Bioventures VII LP are also reporting persons.
• As of June 18, 2026, the reporting persons collectively beneficially own 691,735 shares of Q32 Bio Inc. common stock.
• This represents 4.1% of the total outstanding shares, which were reported as 16,956,415 as of May 5, 2026.
• Abingworth Bioventures VII LP is the record holder of these shares.
• Investment and dispositive power for the shares held by Abingworth Bioventures VII LP have been delegated to Abingworth LLP.
• The reporting persons disclaim beneficial ownership of these shares, except for the specific entities holding them.
• The filing certifies that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it primarily reports an ownership stake without providing operational or financial performance details of Q32 Bio Inc.

Positives

• Significant institutional investor presence indicated by Carlyle Group's stake.
• The filing confirms a substantial ownership percentage (4.1%) by a major investment firm, which could signal confidence in the company's prospects.

Negatives

• The filing does not contain financial performance data, strategic updates, or forward-looking statements, making it difficult to assess the company's operational health.
• The complex ownership structure among the reporting persons might obscure the ultimate beneficial owner's intentions.

Risks

• Potential for future changes in beneficial ownership by the reporting persons, which could impact share price.
• The filing does not provide insight into the strategic rationale behind the investment, leaving room for speculation about future actions.

Future Outlook

This filing is a Schedule 13G, which primarily reports ownership stakes and does not contain forward-looking statements or financial guidance from the company itself.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by major investment firms like The Carlyle Group in biotechnology companies are common, often indicating a belief in the company's technology or market potential, though this filing provides no specific operational details.

Stakeholder Impact

• Shareholders: The increased institutional ownership may be viewed positively, potentially leading to greater scrutiny and strategic direction, but also carries the risk of future stake sales impacting share price.
• Management: The presence of a significant investor like Carlyle may influence strategic decisions and board composition discussions.

Next Steps

• Monitor future filings from The Carlyle Group and Abingworth entities for any changes in their stake.
• Await further disclosures from Q32 Bio Inc. regarding its operational and financial performance.

Key Dates

Keywords

Q32 Bio Inc., Schedule 13G, Carlyle Group, Abingworth LLP, Beneficial Ownership, Common Stock, SEC Filing, Investment Management